Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,711,700 | 1,176,800 | 2,087,103 | 91,635 | -84,031 |
| Depreciation Amortization | 109,500 | 106,900 | 72,420 | 61,397 | 61,398 |
| Income taxes - deferred | 277,300 | 167,400 | -1,512,325 | -120,513 | 16,961 |
| Accounts receivable | -223,400 | -225,600 | -108,152 | -71,759 | -39,095 |
| Accounts payable and accrued liabilities | 51,300 | -22,800 | 36,554 | 8,753 | -11,745 |
| Other Working Capital | -54,400 | -66,100 | 238,020 | 12,764 | -4,988 |
| Other Operating Activity | 381,500 | 432,700 | 456,666 | 862,665 | 297,603 |
| Operating Cash Flow | $3,253,500 | $1,569,300 | $1,270,286 | $844,942 | $236,103 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -259,800 | -75,400 | -95,449 | -99,421 | -56,563 |
| Net Acquisitions | N/A | -1,154,200 | N/A | N/A | N/A |
| Purchase Of Investment | -450,700 | -537,200 | -515,389 | -532,581 | -629,700 |
| Sale Of Investment | 809,900 | 570,800 | 431,576 | 369,214 | 757,562 |
| Other Investing Activity | 0 | -39,300 | -22,896 | -220,541 | -20,061 |
| Investing Cash Flow | $99,400 | $-1,235,300 | $-202,158 | $-483,329 | $51,238 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 13,300 | 10,000 | 20,840 | 34,666 | 86,173 |
| Debt Repayment | -42,300 | -39,200 | -33,388 | -23,602 | -92,597 |
| Common Stock Issued | 264,900 | 343,200 | 289,293 | 344,840 | 68,230 |
| Common Stock Repurchased | -539,100 | -186,000 | -350,043 | 0 | 0 |
| Other Financing Activity | -202,100 | -1,200 | 2,079 | -287,500 | 71,465 |
| Financing Cash Flow | $-505,300 | $126,800 | $-71,219 | $68,404 | $133,271 |
| Exchange Rate Effect | 20,600 | 1,600 | -6,182 | 5,802 | -4,666 |
| Beginning Cash Position | 3,120,700 | 2,658,300 | 1,667,526 | 1,231,707 | 815,761 |
| End Cash Position | 5,988,900 | 3,120,700 | 2,658,253 | 1,667,526 | 1,231,707 |
| Net Cash Flow | $2,868,200 | $462,400 | $990,727 | $435,819 | $415,946 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,253,500 | 1,569,300 | 1,270,286 | 844,942 | 236,103 |
| Capital Expenditure | -259,800 | -75,400 | -95,449 | -99,421 | -56,563 |
| Free Cash Flow | 2,993,700 | 1,493,900 | 1,174,837 | 745,521 | 179,540 |